chevron_leftBack
As of 14 June 2026, Tuoxin Pharmaceutical Group Co.,Ltd. has a market cap of $495.65M USD, ranking #15186 globally and #4737 in China.
It ranks #1344 in the Healthcare sector, and #493 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$495.65MUSD
3.36B CNY
Enterprise Value
$462.59MUSD
3.13B CNY
Revenue (TTM)
$55.17MUSD
373.85M CNY
EBITDA (TTM)
-$2.76MUSD
-18.66M CNY
Net Income (TTM)
-$11.31MUSD
-76.61M CNY
EBITDA Margin
-5%
Profit Margin
-20%
PS Ratio
9.0
PB Ratio
2.3
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Shaohua Yang
open_in_new
Employees
1,543
Founded
2001
Website
tuoxinpharm.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 1.4% | 0.4% | -6% | -12% | -14% | 7.6% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
301089
拓新药业集团股份有限公司 Class A
ISIN: CNE100004YC3
Shares Out.:
Shares Outstanding:
126.545M1
Shares Float:
84.681M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
26.92 CNY |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Tuoxin Pharmaceutical Group Co.,Ltd.
Tuoxin Pharmaceutical Group Co.,Ltd. engages in the research and development, production and sales of nucleoside (acid) APIs and pharmaceutical intermediates in China. It offers nucleoside (acid) products, such as pyrimidine series, purine series, and nucleotide series; nucleoside series, including citicoline sodium, ribavirin, inosine, acyclovir, cytosine, 5-fluorocytosine, cytidine, uridine; and other APIs and pharmaceutical intermediates covering antiviral, anti-tumor, and nervous system. The company was founded in 2001 and is based in Xinxiang, China.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
SSE: 600276
|
$53.85B
11K%
364.89B CNY
|
44.9
|
|
SSE: 603259
|
$49.64B
10K%
336.36B CNY
|
17.2
|
|
SHEK: 3692
|
$28.52B
6K%
223.48B HKD
|
35.7
|
|
SHEK: 1801
|
$18.8B
4K%
147.32B HKD
|
162.3
|
|
SSE: 688506
|
$16.51B
3K%
111.89B CNY
|
-
|
|
SHEK: 9926
|
$16.01B
3K%
125.46B HKD
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
154K%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
110K%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
73K%
|
97.4
|
|
SIX: RO
|
$321.52B
65K%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$288.84B
58K%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$274.65B
55K%
218.9B CHF
|
20.5
|
chevron_leftBack